Cipla Ltd.
BSE: 500087 | Sector: Health care |
NSE: CIPLA | ISIN Code: INE059A01026 |
BSE 00:00 | 28 Oct | 1154.95 |
-10.35 (-0.89%) |
OPEN
1160.75 |
HIGH
1171.80 |
LOW
1153.30 |
NSE 00:00 | 28 Oct | 1155.20 |
-10.70 (-0.92%) |
OPEN
1169.00 |
HIGH
1171.80 |
LOW
1151.00 |
OPEN | 1160.75 |
PREVIOUS CLOSE | 1165.30 |
VOLUME | 17812 |
52-Week high | 1179.90 |
52-Week low | 850.00 |
P/E | 31.86 |
Mkt Cap.(Rs cr) | 93,210 |
Buy Price | 0.00 |
Buy Qty | 0.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
About Cipla Ltd.
Cipla Ltd is one of the leading pharmaceutical companies in India. The company focuses on development of new formulations and has a wide range of pharmaceutical products. The product portfolio includes over 1500 products across wide range of therapeutic categories.Cipla Ltd was incorporated in the year 1935 with the name Chemical Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied th...> More
Cipla Ltd - Key Fundamentals
Parameter | Values | ||
Market Cap | ( |
93,210 | |
EPS - TTM | ( |
[*S] | 36.25 |
P/E Ratio | (X) | [*S] | 31.86 |
Face Value | ( |
2 | |
Latest Dividend | (%) | 250.00 | |
Latest Dividend Date | 08 Aug 2022 | ||
Dividend Yield | (%) | 0.43 | |
Book Value / Share | ( |
[*S] | 278.96 |
P/B Ratio | ( |
[*S] | 4.14 |
News
-
Manyavar, Cipla: 11 stocks that could hold ground even if market corrects
-
Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%
-
Nifty Pharma outshines benchmarks, up 2%; Cipla, Sun Pharma hit 52-wk highs
-
Growth forecast in US market set to drive gains for Cipla stock
-
Cipla Q1 net dips 4% to Rs 686 cr, revenue down 2% on tapering Covid sales
Announcement
-
Statement Of Investor Complaints For The Quarter Ended September 2022
-
Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Cipla Ltd - Financial Results
Particulars ( |
Jun 2022 | Jun 2021 | % Chg |
Net Sales | 5375.19 | 5504.35 | -2.35 |
Other Income | 103.43 | 64.93 | 59.29 |
Total Income | 5478.62 | 5569.28 | -1.63 |
Total Expenses | 4231.84 | 4283.08 | -1.2 |
Operating Profit | 1246.78 | 1286.2 | -3.06 |
Net Profit | 706.56 | 711.8 | -0.74 |
Equity Capital | 161.38 | 161.32 | - |
Cipla Ltd - Peer Group
Company | Price( |
Chg (%) | Mkt Cap ( |
Sun Pharma.Inds. | 989.75 | -2.16 | 237470.71 |
Divi's Lab. | 3547.25 | -2.05 | 94161.75 |
Cipla | 1154.95 | -0.89 | 93210.24 |
Dr Reddy's Labs | 4460.90 | -0.64 | 74273.98 |
Torrent Pharma. | 1600.70 | 0.05 | 54174.09 |
Zydus Lifesci. | 429.50 | -0.96 | 43473.99 |
Cipla Ltd - SHAREHOLDING PATTERN
|
|
Cipla Ltd - Research Reports
Date | Broker | Action | Price | Report |
28/01/2022 | ICICI Direct.com Research | Buy | 904 | |
24/08/2021 | IIFL | Buy | 898 | |
18/05/2021 | Nirmal Bang | Accumulate | 904 |
Cipla Ltd - RETURNS
Period | BSE | NSE | Sensex | NIFTY |
1 Week | 1.81% | 1.80% | 1.10% | 1.20% |
1 Month | 5.32% | 5.29% | 5.94% | 5.51% |
3 Month | 19.35% | 19.41% | 5.46% | 5.06% |
6 Month | 17.58% | 17.73% | 4.24% | 3.14% |
1 Year | 29.51% | 29.54% | -0.04% | -0.39% |
3 Year | 150.37% | 150.56% | 52.76% | 52.98% |
Cipla Ltd - STOCK STRENGTH
Today's Low/High | 1153.30 | 1171.80 | |
Week Low/High | 1132.05 | 1180.00 | |
Month Low/High | 1087.35 | 1180.00 | |
YEAR Low/High | 850.00 | 1180.00 | |
All TIME Low/High | 0.61 | 1180.00 |
Quick Links for Cipla:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices